

Urinary potassium excretion and mortality risk in community-dwelling individuals with and without obesity

Stanley MH Yeung,¹ Anne Nooteboom,¹ Ewout J Hoorn,² Joris I Rotmans,³ Liffert Vogt,⁴ Rudolf A de Boer,⁵ Ron T Gansevoort,¹ Gerjan Navis,¹ Stephan JL Bakker,¹ and Martin H De Borst¹

¹Department of Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; ²Department of Internal Medicine, Division of Nephrology & Transplantation, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, The Netherlands; ³Department of Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands; ⁴Department of Internal Medicine, Section of Nephrology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands; and ⁵Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

ABSTRACT

Background: Potassium intake has been shown to be inversely associated with blood pressure and premature mortality. Previous studies have suggested that the association between potassium intake and blood pressure is modified by obesity, but whether obesity similarly influences the association between potassium intake and mortality is unclear.

Objectives: We investigated whether potassium intake, reflected by 24-h urinary excretion, is associated with all-cause mortality, and explored potential effect modification by obesity.

Methods: We performed a prospective cohort study in community-dwelling individuals. The association between urinary potassium excretion and all-cause mortality was investigated by using multivariable Cox regression. We performed multiplicative interaction analysis and subgroup analyses according to BMI and waist circumference.

Results: In 8533 individuals (50% male), the mean age was 50 ± 13 y, mean urinary potassium excretion was 71 ± 21 mmol/24 h, median BMI (in kg/m²) was 25.6 (IQR: 23.1, 28.4) and mean waist circumference was 89 ± 13 cm. During median follow-up of 18.4 (IQR: 13.5, 18.8) y, 1663 participants died. Low urinary potassium excretion (first compared with third sex-specific quintile) was associated with an increased mortality risk (fully adjusted HR: 1.38; 95% CI: 1.18, 1.61), $P < 0.001$, irrespective of body dimensions (HR range for all body dimensions: 1.36–1.70, all $P < 0.05$). High urinary potassium excretion (fifth compared with third quintile) was associated with increased mortality risk in participants with obesity (BMI ≥ 30 ; HR: 1.52; CI: 1.00, 2.30), but not in participants without obesity (BMI: < 25 ; HR: 0.89; 95% CI: 0.62, 1.26; P -interaction = 0.001).

Conclusions: Low potassium intake was associated with increased mortality risk in community-dwelling individuals. In individuals with obesity, high potassium intake was also associated with increased mortality risk. *Am J Clin Nutr* 2022;116:741–749.

Keywords: potassium intake, nutrition, epidemiology, general population, body dimension, mortality

Introduction

Low urinary potassium excretion is independently associated with a higher risk of cardiovascular disease (CVD) (1) and premature mortality (2,3). Intervention studies have demonstrated that potassium supplementation decreases blood pressure (4). A recent cluster randomized trial demonstrated that a salt substitute, partly replacing sodium with potassium salt, reduced mortality risk in individuals with a history of stroke or age > 60 y and high blood pressure (5). Possible explanations for the beneficial effects of potassium supplementation include potassium-induced natriuresis through inhibition of the sodium-chloride cotransporter and direct vascular effects (6).

Previous studies have demonstrated that individuals with obesity are salt sensitive, as reflected by a stronger effect of sodium loading on blood pressure (7,8). Because potassium-induced natriuresis is considered a main mechanism by which potassium lowers blood pressure, it has also been hypothesized that individuals with obesity are more sensitive to potassium-induced blood pressure-lowering effects. Indeed, a previous

Supported by the Dutch Kidney Foundation (K⁺onsortium, grant CP1601). RADb is supported by grants from the Netherlands Heart Foundation (CVON SHE-PREDICTS-HF, grant 2017-21; CVON RED-CVD, grant 2017-11; CVON PREDICT2, grant 2018-30; and CVON DOUBLE DOSE, grant 2020B005), by a grant from the leDucq Foundation [Cure PhosphoLambaN induced Cardiomyopathy (Cure-PLaN)], and by a grant from the European Research Council (ERC CoG 818715, SECRETE-HF).

Supplemental Figures 1–3 and Supplemental Tables 1–10 are available from the “Supplementary data” link in the online posting of the article at <https://academic.oup.com/ajcn/>.

Address correspondence to SMHY (e-mail: m.h.yeung@umcg.nl).

Abbreviations used: CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; PREVEND, Prevention of Renal and Vascular End-Stage Disease; RAAS, renin-angiotensin-aldosterone system

Received October 27, 2021. Accepted for publication May 13, 2022.

First published online May 17, 2022; doi: <https://doi.org/10.1093/ajcn/nqac137>.

study demonstrated that waist circumference was associated with a stronger blood pressure response to potassium supplementation (9). In line with these findings, a study in Chinese adults reported that the association between urinary potassium excretion and incident hypertension was modified by BMI (10).

Whether the association between potassium intake and mortality is modified by obesity is unknown. Therefore, the aim of the current study was to assess whether urinary potassium excretion is associated with all-cause mortality in a population-based cohort, and whether this association is influenced by BMI or waist circumference.

Methods

Study Population

The Prevention of Renal and Vascular End-Stage Disease (PREVEND) study is a prospective cohort study investigating the natural course of increased amounts of urinary albumin excretion and its relation to renal disease and CVD in a large cohort drawn from the general population. Study details have been described extensively elsewhere (11). In brief, from 1997 and 1998, all inhabitants of Groningen, the Netherlands, aged 28 to 75 y, were sent a questionnaire and a vial to collect a first-morning void urine sample. Pregnant female subjects and insulin users were excluded, since the original aim of PREVEND was to study the relation between albuminuria and outcomes in individuals without type 1 diabetes. Participants with urinary albumin excretion > 10 mg/L in a spot morning urine sample were invited ($n = 7768$), of whom 6000 participants were enrolled. In addition, persons with a lower albumin excretion were randomly invited ($n = 3395$), of whom 2592 were enrolled eventually. These 8592 participants formed the PREVEND cohort and completed the baseline examination, which consisted of 2 visits within 2 wk. In the follow-up period, a portion of the participants completed the subsequent examinations between 2001 and 2008. In the current study, we included only participants who had available 24-h measurement results for urinary sodium and potassium excretion and who completed the baseline examination ($n = 8533$) (Supplemental Figure 1). The PREVEND study has been approved by the medical ethics committee of the University Medical Center Groningen and was performed in accordance with Declaration of Helsinki guidelines. Written informed consent was obtained from all participants.

Data Collection

Each examination consisted of 2 visits to the outpatient clinic, separated by 3 wk. At baseline, participants completed a questionnaire on demographics, history of CVD (defined as self-reported myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass graft, or cerebrovascular accident), type 2 diabetes (defined as self-reported type 2 diabetes, use of oral hypoglycemic drugs, or glucose measurement), smoking habits, alcohol usage, education [categorized into low (primary education up to those completing intermediate vocational education), average (higher secondary education), and high (higher vocational education and university)] and medication use. Information on medication use at baseline was amended with data acquired from IADB.nl, a database

comprising pharmacy dispensing data from all community pharmacies in Groningen.

The proportion of participants who had received at ≥ 1 prescription during the 6 mo before screening is presented as prevalent drug use at baseline. Use of lipid-lowering, oral hypoglycemic, and antihypertensive drugs was recorded. Antihypertensive drugs were defined as angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, thiazide diuretics, loop diuretics, beta-blockers, calcium channel blockers, potassium sparing diuretics, or other antihypertensives. In the last week before the second visit (i.e., visit 2/2 of the baseline examination), participants collected 2 consecutive 24-h urine samples. The collected urine was stored cold at 4°C for a maximum of 4 d. After the collected urine was received, urine specimens were stored at -20°C. We used the average of both 24-h urine collections that were part of the baseline examination in our analyses. Furthermore, fasting blood samples were taken and stored at -80°C. During the visit, blood pressure was assessed on the right arm in the supine position every minute for 10 and 8 min, respectively, by an automatic Dinamap XL Model 9300 series device. The mean of the last 2 recordings from each visit was used. The mean arterial pressure was calculated using these recordings. BMI was calculated using weight (kilograms) divided by height squared (square meters). Minimum waist circumference was measured on bare skin at the natural indentation between the 10th rib and the iliac crest. When there was no indentation, we measured it in the middle between navel and rib cage. Smoking status was categorized as current or not. Alcohol intake was categorized as current or no alcohol consumption. The primary endpoint was all-cause mortality. The outpatient program of the hospital uses a continuous surveillance system by the municipal registration of death to ensure up-to-date information on patient status (alive or deceased).

Laboratory Measurements

The presence of potassium, sodium, urea, and creatinine in urine samples was determined with a MEGA clinical chemistry analyzer (Merck). Potassium, and sodium were determined by indirect potentiometry, and urea was determined by a photometric test with the urease-GIDH method. Estimated glomerular filtration rate (eGFR) was calculated based on the combined creatinine and cystatin C Chronic Kidney Disease-Epidemiology Collaboration equation (12). Serum and urinary creatinine, plasma total cholesterol, and triglycerides were determined from fasting blood samples by using Kodak Ektachem dry chemistry (Eastman Kodak). Plasma HDL cholesterol was measured with a homogeneous method (direct HDL, Aeroset TM System, Abbott Laboratories). Plasma renin concentration was measured using an automated sandwich immunochemiluminescent assay (LIAISON®, Diasorin). Serum aldosterone concentration was measured using a competition-based radioimmunoassay (ALDOCK-2, Diasorin). Serum cystatin C concentrations were measured by a Gentian Cystatin C Immunoassay (Gentian AS) on a modular analyzer (Roche Diagnostics). Urinary albumin concentration was determined by nephelometry (Dade Behring Diagnostic). Urinary albumin-to-creatinine ratio (ACR) was calculated by dividing the urinary albumin concentration (mg/L) by the urinary creatinine concentration (mmol/L).

Statistical Analyses

Baseline characteristics are presented according to quintiles of urinary potassium excretion. Continuous data are presented as mean \pm SD or as median (IQR) in case of nonnormal distribution. Categorical data are presented as percentiles. Nonnormally distributed variables were transformed before being used in subsequent analyses if needed. We aimed to identify correlates of urinary potassium excretion by using a chi-square test, 1-way ANOVA, or Kruskal Wallis test for nominal, normally distributed, and nonhomogeneity or nonnormally distributed data, respectively. In order to avoid potential bias from exclusion of patients with missing values, we used multiple imputation (fully conditional specification (Markov Chain Monte-Carlo) to obtain 5 imputed datasets (13). Rubin's rules were used to obtain pooled estimates of the regression coefficients and their SEs across imputed datasets (14).

We used Cox proportional multivariable hazards regression analyses to investigate the associations of urinary potassium excretion, in sex-specific quintiles, with all-cause mortality. The third (middle) quintile was defined as the reference category. Survival time was defined from baseline until date of death, or 1 January 2017 (end of follow-up). We adjusted for confounders and we built the fully adjusted model as follows: sex-specific quintiles of urinary potassium excretion adjusted for age, BMI (indirect measurement of caloric intake), eGFR, ACR (kidney function), risk factors for mortality, history of CVD, type 2 diabetes, education level, alcohol consumption, smoking, triglyceride-HDL ratio, urinary creatinine excretion as a marker for muscle mass (15), urinary urea excretion as a marker of protein intake, urinary sodium excretion, and use of oral hypoglycemic, antihypertensive, and cholesterol lowering drugs. In addition, we adjusted for aldosterone, renin, and blood pressure to find potential mediation effects of these variables. Nonlinearity was tested by using a likelihood ratio test, comparing nested models with linear or linear and cubic terms. We used restricted cubic spline with 3 knots (5th, 50th, and 95th percentile) to visualize the continuous association between urinary potassium excretion and risk of all-cause mortality by fitting the Cox regression analysis of the final model. Furthermore, we investigated whether urinary potassium excretion was associated with CVD and non-CVD mortality.

We analyzed potential effect modification by BMI and waist circumference by fitting models containing both main effects and their cross-products terms in the all-cause mortality analyses. We categorized participants according to 3 BMI groups (<25 , 25–30, and ≥ 30 , measured in kg/m^2) or waist circumference (<82 , 82–94, ≥ 94 cm) and quintiles of urinary potassium excretion. The groups with BMI <25 and waist circumference 82–94 cm, respectively, were defined as the reference categories.

To examine the robustness of the main findings, we performed sensitivity analyses by excluding subjects with potential inadequacy of 24-h collection by comparing the actual 24-h creatinine excretion with creatinine excretion as predicted by body dimensions, age, and sex (16). In addition, to further increase the robustness of the main findings, we performed sensitivity analyses by excluding participants with history of CVD or malignancy and participants who developed chronic kidney disease (defined as a combination of reaching an eGFR of <60 mL/min per 1.73 m^2 or a urinary albumin excretion of

>30 mg/24 h de novo, or both), cardiovascular event, or new-onset malignancy. Cardiovascular event was coded according to the *International Classification of Diseases, Ninth Revision*, and consisted of the combined incidence of fatal and nonfatal events of ischemic heart disease, stroke, and vascular interventions such as percutaneous transluminal angioplasty or bypass grafting of aorta and peripheral vessels. Ischemic heart disease events were defined as acute myocardial infarction (code 410), acute and subacute ischemic heart disease (code 411), coronary artery bypass grafting (code 414), or percutaneous transluminal coronary angioplasty (code 36.0). Stroke events were defined as subarachnoid hemorrhage (code 430), intracerebral hemorrhage (code 431), other intracranial hemorrhage (code 432), or occlusion or stenosis of the precerebral (code 433) or cerebral (code 434) arteries. In addition, strokes were subclassified into hemorrhagic strokes (codes 430–431), ischemic strokes (codes 433–434), or unspecified strokes (code 432). Data on fatal CVD were received through the municipal register. Cause of death was obtained by linking the number of the death certificate to the primary cause of death as coded by the Dutch Central Bureau of Statistics. New-onset malignancy cases (included all malignancies, except nonmelanoma skin cancers) were provided through the nationwide network and registry of histopathology and cytopathology in the Netherlands (PALGA) (17) and were reviewed and adjudicated by an independent committee. To analyze the long-term effect of potassium intake on the outcome, sensitivity analysis was done by excluding participants who died or were lost to follow-up ≤ 1 y after baseline. As the last step, sensitivity analyses were done by adjustment for renin-angiotensin-aldosterone system (RAAS) inhibitor or diuretic use in the follow-up and by repeating the main analysis while excluding participants who were using RAAS inhibitors or diuretics.

All statistical analyses were performed with SPSS software version 23.0 for Windows (IBM), and R version 4.0.1 (<http://cran.r-project.org/>). In all analyses, a 2-sided P -value < 0.05 was considered significant.

Results

Patient Characteristics

Data were analyzed from 8533 individuals (50% male) with a mean age of 50 ± 13 y. Mean urinary potassium excretion was 71 ± 21 mmol/24 h, median BMI was 25.6 (IQR 23.1, 28.4), and mean waist circumference 89 ± 13 cm. Baseline characteristics according to sex-specific quintiles of urinary potassium excretion are displayed in Table 1. Urinary potassium excretion correlated with urinary sodium excretion ($r = 0.45$, $P < 0.001$), and individuals in the highest urinary potassium excretion quintiles also had the highest urinary sodium excretion [median 163 (IQR 129–202) mmol/24 h, P -trend < 0.001], as well as higher urinary urea excretion, suggesting higher protein intake (Table 1). Participants with a higher urinary potassium excretion had a slightly higher BMI, while those with a lower urinary potassium excretion had higher total cholesterol, triglycerides, and triglyceride/HDL ratio and lower HDL cholesterol. Higher serum aldosterone concentrations were seen in participants with higher urinary potassium excretion, but plasma renin was not

TABLE 1 Baseline characteristics according to sex specific quintiles of urinary potassium excretion in 8533 participants of PREVENT¹

	Quintiles of total urinary potassium excretion					P-trend ²
	Total	I	II	III	IV	
Sex-specific quintiles, mmol/24 h						
Male (n = 4301)	77 ± 22	<59	59–70	70–81	81–94	>94
Female (n = 4291)	66 ± 19	<50	50–60	60–69	69–81	>81
Urinary potassium excretion, mmol/24 h	71 ± 21	44 ± 9	60 ± 6	70 ± 6	80 ± 7	101 ± 15
Age, y	50 ± 13	52 ± 13	51 ± 13	50 ± 13	49 ± 12	47 ± 11
BMI	25.6 (23.1–28.4)	25.4 (22.8–28.1)	25.6 (23.2–28.2)	25.7 (23.2–28.4)	25.5 (23.1–28.4)	25.7 (23.4–28.9)
Waist circumference, cm	89 ± 13	89 ± 13	89 ± 13	88 ± 13	89 ± 13	89 ± 13
Systolic blood pressure, mm Hg	126 (114–141)	127 (114–143)	127 (114–142)	125 (114–140)	125 (114–140)	125 (113–139)
Diastolic blood pressure, mm Hg	73 (67–80)	74 (67–81)	74 (68–81)	73 (67–80)	73 (67–79)	72 (67–79)
Anthypertensive drugs	1164 (14)	290 (17)	255 (15)	249 (15)	190 (12)	180 (11)
ACE-inhibitors/ARB	404 (6)	98 (7)	86 (6)	88 (6)	66 (5)	66 (5)
Thiazide diuretics	201 (3)	49 (3)	42 (3)	38 (3)	23 (2)	49 (4)
Loop diuretics	66 (0.9)	19 (1)	11 (0.8)	11 (0.7)	14 (1)	11 (0.8)
Potassium-sparing diuretics	14 (0.2)	3 (0.2)	3 (0.2)	1 (0.1)	4 (0.3)	3 (0.2)
Lipid-lowering drugs	346 (5)	92 (6)	77 (6)	87 (6)	44 (3)	46 (3)
Oral hypoglycemic drugs	119 (2)	28 (2)	24 (2)	24 (2)	22 (2)	21 (2)
Education level						
Low	3674 (43)	880 (52)	824 (49)	719 (42)	678 (40)	573 (34)
Middle	1943 (23)	386 (23)	399 (24)	392 (23)	384 (23)	382 (23)
High	2874 (34)	429 (25)	474 (28)	588 (35)	640 (38)	743 (44)
Smoking status, ever	2912 (34)	679 (40)	607 (36)	589 (35)	527 (31)	510 (31)
Alcohol consumption, yes	6328 (75)	1114 (66)	1246 (73)	1301 (76)	1309 (77)	1358 (80)
CVD, yes	449 (5)	141 (8)	96 (6)	93 (5)	65 (4)	54 (3)
Type 2 diabetes, yes	245 (3)	51 (3)	52 (3)	44 (3)	54 (3)	44 (3)
History of malignancy, yes	134 (2)	28 (2)	33 (2)	26 (2)	24 (1)	23 (1)
Plasma creatinine, μmol/L	70.7 (61.0–80.4)	69.6 (61.0–80.4)	70.7 (61.0–80.4)	70.7 (62.1–80.4)	70.7 (62.1–80.4)	70.7 (62.1–80.4)
eGFR, mL/min-1.73m ²	93.4 ± 21.3	90.9 ± 22.5	92.2 ± 21.9	93.1 ± 21.3	94.3 ± 20.6	96.3 ± 19.6
Stage 1 (eGFR ≥ 90)	4455 (56)	803 (51)	860 (54)	875 (55)	929 (58)	988 (62)
Stage 2 (eGFR ≥ 60 and <90)	3027 (38)	637 (41)	605 (38)	633 (40)	590 (37)	562 (35)
Stage 3 (eGFR ≥ 30 and <60)	459 (6)	126 (8)	121 (8)	88 (6)	78 (5)	46 (3)
Stage 4 (eGFR ≥ 15 and <30)	19 (0.2)	6 (0.4)	6 (0.4)	4 (0.3)	3 (0.2)	0 (0)
Stage 5 (eGFR <15)	2 (0)	2 (0.1)	0 (0)	0 (0)	0 (0)	0 (0)
Plasma albumin, g/L	45.8 ± 2.7	45.6 ± 2.8	45.6 ± 2.8	45.9 ± 2.7	45.9 ± 2.6	45.9 ± 2.6
Plasma potassium, mmol/L	4.4 ± 0.7	4.3 ± 0.4	4.4 ± 0.6	4.4 ± 0.7	4.4 ± 0.8	4.4 ± 0.6
Plasma sodium, mmol/L	142 ± 2.3	142 ± 2.4	142 ± 2.5	142 ± 2.4	142 ± 2.3	142 ± 2.0
Serum aldosterone, pmol/L	118 (93–153)	116 (89–155)	120 (94–157)	120 (93–155)	117 (92–157)	123 (96–160)
Plasma renin, ng/L	18 (1–29)	18 (10–29)	19 (11–30)	18 (11–29)	19 (11–29)	18 (12–28)

(Continued)

TABLE 1 (Continued)

	Quintiles of total urinary potassium excretion					P-trend ²	
	Total	I	II	III	IV		V
Total cholesterol, mmol/L	5.6 (4.9–6.3)	5.6 (4.9–6.4)	5.6 (4.9–6.4)	5.6 (4.9–6.4)	5.5 (4.9–6.3)	5.4 (4.8–6.2)	<0.001
HDL cholesterol, mmol/L	1.32 ± 0.40	1.30 ± 0.39	1.31 ± 0.40	1.32 ± 0.39	1.33 ± 0.40	1.34 ± 0.41	0.02
Triglycerides, mmol/L	1.16 (0.85–1.68)	1.22 (0.90–1.75)	1.19 (0.85–1.71)	1.18 (0.86–1.69)	1.11 (0.82–1.66)	1.11 (0.82–1.63)	<0.001
Triglyceride/HDL ratio ³	2.10 (1.30–3.51)	2.27 (1.41–3.73)	2.15 (1.35–3.56)	2.12 (1.31–3.47)	2.00 (1.23–3.42)	1.95 (1.23–3.33)	<0.001
Urinary sodium excretion, mmol/24 h	136 (106–170)	109 (82–138)	128 (101–157)	139 (109–171)	145 (118–178)	163 (129–202)	<0.001
Sodium/potassium ratio	2.0 (1.6–2.5)	2.5 (1.9–3.0)	2.1 (1.7–2.6)	2.0 (1.6–2.4)	1.8 (1.5–2.2)	1.6 (1.3–2.0)	<0.001
Urinary urea excretion, mmol/24 h	354 ± 106	269 ± 81	323 ± 82	360 ± 88	383 ± 93	436 ± 104	<0.001
Urinary creatinine excretion, mmol/24 h	12.3 ± 3.5	10.3 ± 3.1	11.6 ± 3.0	12.4 ± 3.1	13.0 ± 3.5	14.1 ± 3.8	<0.001
ACR, mg/g in 24-h urine	0.80 (0.54–1.49)	0.86 (0.56–1.72)	0.83 (0.55–1.56)	0.79 (0.53–1.43)	0.78 (0.54–1.43)	0.74 (0.52–1.39)	<0.001

¹Data are presented as *n* (%), means ± SDs, or medians (IQRs) for nominal, normally distributed, and non-normally distributed data, respectively. ACE, angiotensin-converting enzyme; ACR, albumin-to-creatinine ratio; ARB, angiotensin receptor blocker; CRP, C-reactive protein; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; PTH, parathyroid hormone.

²The *P*-value represents the *P* for trend in the chi-square test, 1-way-ANOVA, or Kruskal–Wallis test for nominal, normally distributed and nonhomogeneity or nonnormally distributed data, respectively.

³Triglyceride/HDL ratio was calculated using mg/dL units.

different. The number of participants with missing data for each variable is presented in **Supplemental Table 1**.

Associations with Mortality

During a median follow-up of 18.4 y (IQR: 13.5, 18.8), 1663 participants died (19%), and the mortality rate was distributed according to the sex-specific quintiles as follows: quintile I: 477 (28%); II: 364 (21%); III: 313 (18%); IV: 280 (16%); and V: 222 (13%). Upon Cox proportional hazards regression analysis, participants in the lowest sex-specific quintile of urinary potassium excretion had a significantly increased risk of all-cause mortality compared with participants the third quintile (fully adjusted HR: 1.38; 95% CI: 1.18, 1.61; *P* < 0.001, **Table 2** and **Figure 1**). The HR of the highest sex-specific urinary potassium excretion quintile was similar to the reference (third) quintile (HR: 1.02; 95% CI: 0.85, 1.22). Further adjustment for serum aldosterone, plasma renin, and systolic and diastolic blood pressure did not materially change the results (**Supplemental Table 2**). Of all mortality cases, 441 were related to CVD and 1222 were not related to CVD. Participants in the lowest sex-specific quintile of urinary potassium excretion showed a trend in increased risk of CVD mortality compared with participants in the third quintile (fully adjusted HR: 1.33; 95% CI: 0.99, 1.78; *P* = 0.06, **Supplemental Table 3**). Furthermore, participants in the lowest sex-specific quintile of urinary potassium excretion had a significantly increased risk of non-CVD mortality compared with the third quintile (fully adjusted HR: 1.40; 95% CI: 1.17, 1.68; *P* < 0.001, **Supplemental Table 3**).

Interaction with Body Dimensions

Low urinary potassium excretion was associated with a higher risk of all-cause mortality in all BMI and waist circumference subgroups (**Table 3**, **Figure 2A** and **B**). Furthermore, high urinary potassium excretion was associated with a higher mortality risk in individuals with a BMI ≥ 30 or a waist circumference ≥ 94 cm, but not in those in the intermediate or lower BMI or waist circumference categories (*P*-interaction < 0.01; **Table 3** and **Figure 2A** and **B**). Further adjustment for serum aldosterone, plasma renin, and systolic and diastolic blood pressure did not materially change the results in the individuals with highest BMI and waist circumference (**Supplemental Table 4**). Urinary sodium excretion increased over quintiles of potassium excretion in participants with obesity (**Supplemental Table 5**), and only 9% of participants with obesity in the highest potassium quintile had a sodium excretion < 120 mmol/24 h.

Sensitivity Analyses

In sensitivity analyses, we excluded participants with potentially inadequate urine collection (*n* = 183). This exclusion had only marginal effects on the sizes of associations affecting all-cause mortality. The associations remained between the lowest sex-specific urinary potassium excretion quintile (**Supplemental Table 6** and **Supplemental Figure 2**). Baseline BMI and waist circumference still modified the associations between urinary potassium and mortality (all *P*-interaction < 0.05),

TABLE 2 Association of urinary potassium excretion with risk of all-cause mortality in 8533 subjects of PREVEND¹

	Quintiles of urinary potassium excretion, mmol/24 h				
	I	II	III	IV	V
Sex-specific values, mmol/24 h					
Male (<i>n</i> = 4301)	<59	59–70	70–81	81–94	>94
Female (<i>n</i> = 4291)	<50	50–60	60–69	69–81	>81
HR adjusted for age	1.43 (1.24, 1.65)***	1.12 (0.96, 1.30)	1.0 (ref)	0.94 (0.80, 1.10)	0.98 (0.82, 1.16)
Fully adjusted HR ²	1.38 (1.18, 1.61)***	1.13 (0.97, 1.32)	1.0 (ref)	0.99 (0.84, 1.16)	1.02 (0.85, 1.22)

¹Data are presented as HRs (95% CIs) unless otherwise indicated. *P*-values are shown as: * ≤ 0.05 , ** ≤ 0.01 , *** ≤ 0.001 . ACR, albumin-to-creatinine ratio; eGFR, estimated glomerular filtration rate; PREVEND, Prevention of Renal and Vascular End-Stage Disease, ref = reference.

²Model additionally adjusted for BMI, eGFR, urinary ACR, type 2 diabetes, education level, alcohol consumption, smoking, history of cardiovascular disease, triglyceride/HDL ratio, urinary creatinine, urea, sodium excretion, and antihypertensive, oral hypoglycemic, and lipid lowering drugs.

in line with the results of the main analyses (**Supplemental Table 7** and **Supplemental Figure 3A** and B). Furthermore, when participants with a history of CVD, malignancy, incident chronic kidney disease, cardiovascular event, or malignancy were excluded, low urinary potassium excretion remained associated with all-cause mortality (HR: 1.71; 95% CI: 1.16; 2.52), **Supplemental Table 8**). Similar results were obtained when participants were excluded who died or were lost to follow-up at ≤ 1 y after baseline assessment (**Supplemental Table 9**). Finally, additional adjustment for use of RAAS inhibitors or diuretics during follow-up or exclusion of participants using

RAAS inhibitors or diuretics during follow-up did not materially change the results (**Supplemental Table 10**).

Discussion

In this study, we found a reverse J-shaped association between urinary potassium excretion and all-cause mortality in a large, well-characterized, general population-based cohort with 18.4 y of follow-up. Additionally, we found significant effect modification associated with body dimensions.




FIGURE 1 Associations between urinary potassium excretion and all-cause mortality in 8533 participants. Data were fit by a Cox proportional hazards regression model based on restricted cubic splines (5th, 50th, and 95th percentile knots) and adjusted for age, sex, eGFR, BMI, urinary albumin-to-creatinine excretion, type 2 diabetes, education level, alcohol consumption, smoking, history of CVD, triglyceride HDL ratio, urinary creatinine excretion, urea excretion, sodium excretion, antihypertensive, oral hypoglycemic and lipid lowering drugs. The gray area represents the 95% CI. Linear $P = 0.003$, nonlinear $P < 0.001$. CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate.

TABLE 3 Association of urinary potassium excretion with all-cause mortality in body dimensions subgroups¹

Sex-specific quintiles of urinary potassium excretion, mmol/24 h					
I	II	III	IV	V	<i>P</i> -interaction ²
BMI <25					
165/738	102/740	90/739	79/740	48/738	0.001
1.70 (1.31, 2.21)***	1.10 (0.83, 1.47)	1.0 (ref.)	1.17 (0.86, 1.59)	0.89 (0.62, 1.26)	
BMI 25–30					
229/700	198/702	154/701	132/701	109/701	0.002
1.36 (1.04, 1.79)*	1.34 (1.02, 1.76)*	1.11 (0.84, 1.47)	0.90 (0.67, 1.20)	1.11 (0.82, 1.51)	
BMI ≥30					
83/266	72/267	68/267	63/268	64/265	0.002
1.47 (1.00, 2.16)*	1.35 (0.90, 2.02)	1.19 (0.79, 1.78)	1.11 (0.74, 1.67)	1.52 (1.00, 2.30)*	
Waist circumference <82 cm					
91/576	49/577	45/577	42/577	28/577	0.002
1.62 (1.19–2.23)**	0.89 (0.62, 1.28)	0.84 (0.56, 1.21)	1.08 (0.74, 1.57)	0.90 (0.58, 1.40)	
Waist circumference 82–94 cm					
148/541	112/541	85/542	75/541	52/541	0.002
1.42 (1.08, 1.86)*	1.22 (0.92, 1.62)	1.0 (ref.)	1.01 (0.74, 1.38)	0.91 (0.64, 1.28)	
Waist circumference ≥94 cm					
236/588	208/591	190/586	150/589	142/589	0.002
1.50 (1.16, 1.94)**	1.46 (1.13, 1.90)**	1.35 (1.04, 1.76)*	1.14 (0.86, 1.50)	1.36 (1.02, 1.80)*	

¹Data are presented as *n* events/*n* participants or HRs (95% CIs) unless otherwise indicated. ACR, albumin-to-creatinine ratio; eGFR, estimated glomerular filtration rate.

²*P*-values shown as: * ≤0.05, ** ≤ 0.01, *** <0.001. Multivariable adjusted Cox regression models adjusted for age, BMI, eGFR, urinary ACR, type 2 diabetes, education level, alcohol consumption, smoking, history of cardiovascular disease, triglyceride HDL ratio, urinary creatinine, urea, sodium excretion, and antihypertensive, oral hypoglycemic, and lipid-lowering drugs.

Prior studies showed effect modification by BMI for the association between urinary potassium excretion and incident hypertension (10). Furthermore, a larger waist circumference was associated with a stronger blood pressure-lowering effect of potassium supplementation (9). In the current study, we found that this higher potassium intake was associated with a

higher mortality risk in individuals with obesity. A possible explanation is that urinary potassium excretion correlated with urinary sodium excretion, individuals in the highest potassium quintile excreted higher amounts of sodium than those in lower quintiles, and nearly all individuals with obesity and with high potassium excretion had concomitant sodium intake




FIGURE 2 3D plots depicting the multivariable adjusted association between urinary potassium excretion (BMI, A; Waist circumference, B) and all-cause mortality in 8533 participants. Cox proportional hazards regression model was adjusted for age, sex, eGFR, BMI, urinary albumin-to-creatinine excretion, type 2 diabetes, education level, alcohol consumption, smoking, history of CVD, triglyceride HDL ratio, urinary creatinine excretion, urea excretion, sodium excretion, antihypertensive, oral hypoglycemic and lipid lowering drugs. CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate.

>120 mmol/24 h (18). Therefore, concurrent high sodium intake could have blunted the inverse association between urinary potassium excretion and mortality in participants with obesity, despite adjustment for urinary sodium excretion. In line with our findings, another observational study found that the association of high potassium intake with lower risks of cardiovascular events and death was blunted by concomitant high sodium intake (19). Alternatively, other unhealthy lifestyle-related factors could also have confounded our results. Our results are in contrast with findings from the NHANES3, where the inverse association between potassium intake by 24-h dietary recall and all-cause mortality was significant in overweight participants, but not in non-overweight participants (20). Other studies, including the more recent PURE (Prospective Urban Rural Epidemiology) study, found no interaction by BMI for the association between urinary potassium excretion and blood pressure (21), all-cause mortality, or CVD (2). Discrepancies between our results and previous findings might be explained by differences in study population ethnicity, study era, assessment of potassium intake (dietary recall, spot urines or 24-h urines), BMI cutoffs, study outcomes, and concomitant sodium intake. Our results set the stage for further studies on the impact of increasing potassium intake in individuals with obesity, also given the increasing prevalence of obesity around the world (22).

Our finding that in the full cohort low potassium intake was associated with an increased mortality risk is in line with several previous studies (1–3). In these studies, the risk of all-cause mortality increased if potassium intake was <2.1–2.5 g/d. In line with this finding, we found an independent relation between a low 24-h urinary potassium excretion (<2.7 g/d) and a higher risk for all-cause mortality in the general population, which supports the WHO recommendation of potassium intake of at least 3.5 g/d (23). Further analyses of cause-specific mortality outcomes showed that urinary potassium excretion was associated with both CVD-related and non-CVD-related mortality. A trend was found in the association with CVD mortality, probably due to a smaller number of events, compared with non-CVD-related mortality. It has been reported that low potassium intake may increase sodium reabsorption, resulting in a higher blood pressure (24). Moreover, endothelial and vascular function are disturbed by low potassium intake, and this effect may be reversed by potassium supplementation (25). Finally, low urinary potassium excretion might reflect lower overall nutritional intake (26), and malnourishment might drive the increased mortality risk. On the other hand, a recent trial in >20,000 individuals at cardiovascular risk showed that a salt substitute that partly replaced sodium with potassium salt lowered the risk of mortality and cardiovascular events (5). These findings suggest that potassium supplementation has specific beneficial effects, although whether the outcomes were driven by potassium supplementation or sodium restriction remains unclear.

Our study has several strengths and limitations. We performed this study in a large and well-characterized cohort with a median follow-up of >18 y. Although no repeated 24-h urinary measurements were available during follow-up (27), 2 independent 24-h urine collections at baseline were used to estimate potassium intake. Findings from our cohort, which consisted predominantly of individuals of European ancestry, may not be generalizable to other populations (28). Our findings

are observational, and therefore, residual confounding might persist despite multivariable adjustment. Our study focused on potassium and sodium as individual factors and lacked data on dietary contents, such as fruit and vegetable intake. Some dietary patterns high in potassium, such as the Dietary Approach to Stop Hypertension diet and the Mediterranean diet, also contain other beneficial micronutrients (29,30). Therefore, intake of other nutrients or minerals might have confounded our results.

In conclusion, we found that low urinary potassium excretion was associated with a higher mortality risk in community-dwelling individuals. We found effect modification by body dimensions. In participants with obesity, the association of urinary potassium excretion displayed a U-shaped curve, whereas in participants without obesity this association showed a reverse J-shaped curve. The higher mortality risk in individuals with obesity and with high urinary potassium excretion might be explained by concomitant high sodium intake or other confounding lifestyle-related factors. Our findings set the stage for prospective studies addressing the impact of increasing potassium intake on clinical outcomes in individuals with obesity.

This work is supported by the Dutch Kidney Foundation (K + onsortium, grant CP1601). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

The authors' responsibilities were as follows—SMHY: performed the statistical analyses and wrote the paper; AN: wrote the paper; EJH, JIR, LV, RAdB, GN: critically revised the manuscript; RTG: supervised data collection, and critically revised the manuscript; SJLB: critically revised the manuscript, and edited the manuscript; MHdB: assisted in statistical analyses, critically revised the manuscript, and had primary responsibility; and all authors: read and approved the final manuscript. Author disclosures: The UMCG, which employs several of the authors, has received research grants and/or fees from mbh, Ionis Pharmaceuticals, Inc., Novo Nordisk, Roche, Sanofi Genzyme, and Vifor Pharma (outside the submitted work). RAdB received speaker fees from Abbott, AstraZeneca, Bayer, Novartis, and Roche (outside the submitted work). MHdB received speaker fees from Astellas, AstraZeneca, Bayer, Kyowa Kirin, Sanofi Genzyme, and Vifor Pharma (outside the submitted work). All other authors report no conflicts of interest.

Data Availability

Data described in the manuscript, code book, and analytic code will be made available upon request pending.

References

- Kieneker LM, Feskens EJM, Geleijnse JM, Bakker SJL, Joosten MM, Gansevoort RT, et al. Urinary potassium excretion and risk of cardiovascular events. *Am J Clin Nutr* 2016;103(5):1204–12.
- O'Donnell M, Mentz A, Rangarajan S, McQueen MJ, Wang X, Liu L, et al. Urinary sodium and potassium excretion, mortality, and cardiovascular events. *N Engl J Med* 2014;371(7):612–23.
- Nohara-Shitama Y, Adachi H, Enomoto M, Fukami A, Kumagai E, Nakamura S, et al. Twenty-four-hour urinary potassium excretion, but not sodium excretion, is associated with all-cause mortality in a general population. *J Am Heart Assoc* 2018;7(1):1–7.
- Filippini T, Violi F, D'Amico R, Vinceti M. The effect of potassium supplementation on blood pressure in hypertensive subjects: a systematic review and meta-analysis. *Int J Cardiol* 2017;230:127–35.
- Neal B, Wu Y, Feng X, Zhang R, Zhang Y, Shi J, et al. Effect of salt substitution on cardiovascular events and death. *N Engl J Med* 2021;385(12):1067–77.
- Gritter M, Rotmans JJ, Hoon EJ. Role of dietary K+ in natriuresis, blood pressure reduction, cardiovascular protection, and renoprotection. *Hypertension* 2019;73(1):15–23.

7. Rocchini AP, Key J, Bondie D, Chico R, Moorehead C, Katch V, et al. The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. *N Engl J Med* 1989;321(9):580–5.
8. Tuck ML. Role of salt in the control of blood pressure in obesity and diabetes mellitus. *Hypertension* 1991;17(1_Suppl):1135–.
9. Xing X, Liu F, Yang X, Huang C, Zhang D, Chen S, et al. Central blood pressure responses to dietary sodium and potassium interventions. *Am J Hypertens* 2018;31(5):582–9.
10. Yan L, Bi Z, Tang J, Wang L, Yang Q, Guo X, et al. Relationships between blood pressure and 24-hour urinary excretion of sodium and potassium by body mass index status in Chinese adults. *J Clin Hyperten* 2015;17(12):916–25.
11. Hillege HL, Janssen WMT, Bak AAA, Diercks GFH, Grobbee DE, Crijns HJGM, et al. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. *J Intern Med* 2001;249(6):519–26.
12. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. Vol. 367, *N Engl J Med* 2012;367(1):20–9.
13. Sterne JAC, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. *BMJ* 2009;338:b2393.
14. Harel O, Zhou X-H. Multiple imputation: review of theory, implementation and software. *Stat Med* 2007;26(16):3057–77.
15. Welle S, Thornton C, Totterman S, Forbes G. Utility of creatinine excretion in body-composition studies of healthy men and women older than 60 y. *Am J Clin Nutr* 1996;63(2):151–6.
16. Ix JH, Wassel CL, Stevens LA, Beck GJ, Froissart M, Navis G, et al. Equations to estimate creatinine excretion rate: the CKD epidemiology collaboration. *Clin J Am Soc Nephrol* 2011;6(1):184–91.
17. Casparie M, Tiebosch ATMG, Burger G, Blauwgeers H, van de Pol A, van Krieken JHJM, et al. Pathology databanking and biobanking in the Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. *Anal Cell Pathol* 2007;29(1):19–24.
18. Chen X, Zhang Z, Yang H, Qiu P, Wang H, Wang F, et al. Consumption of ultra-processed foods and health outcomes: a systematic review of epidemiological studies. *Nutr J* 2020;19(1):86.
19. O'Donnell M, Mente A, Rangarajan S, McQueen MJ, O'Leary N, Yin L, et al. Joint association of urinary sodium and potassium excretion with cardiovascular events and mortality: prospective cohort study. *BMJ* 2019;364:1772.
20. Yang Q, Liu T, Kuklina E V, Flanders WD, Hong Y, Gillespie C, et al. Sodium and potassium intake and mortality among US adults: prospective data from the third National Health and Nutrition Examination Survey. *Arch Intern Med* 2011;171(13):1183–91.
21. Dyer AR, Elliott P, Shipley M, Stamler R, Stamler J. Body mass index and associations of sodium and potassium with blood pressure in INTERSALT. *Hypertension* 1994;23(6 Pt 1):729–36.
22. Janssen F, Bardoutsos A, Vidra N. Obesity prevalence in the long-term future in 18 European countries and in the USA. *Obes Facts* 2020;13(5):514–27.
23. World Health Organization [internet]. Guideline: potassium intake for adults and children. Geneva: World Health Organization; 2012. Available from: <https://www.who.int/publications/i/item/9789241504829>.
24. Coruzzi P, Brambilla L, Brambilla V, Gualerzi M, Rossi M, Parati G, et al. Potassium depletion and salt sensitivity in essential hypertension. *J Clin Endocrinol Metabol* 2001;86(6):2857–62.
25. Blanch N, Clifton PM, Petersen KS, Keogh JB. Effect of sodium and potassium supplementation on vascular and endothelial function: a randomized controlled trial. *Am J Clin Nutr* 2015;101(5):939–46.
26. Mente A, Irvine EJ, Honey RJDA, Logan AG. Urinary potassium is a clinically useful test to detect a poor quality diet. *J Nutr* 2009;139(4):743–9.
27. Olde Engberink RH, van den Born B-JH, Peters-Sengers H, Vogt L. Estimation of potassium intake: single versus repeated measurements and the associated cardiorenal risk. *Eur J Clin Nutr* 2022;76(2):309–136.
28. Aviv A, Hollenberg NK, Weder A. Urinary potassium excretion and sodium sensitivity in blacks. *Hypertension* 2004;43(4):707–13.
29. Soltani S, Arablou T, Jayedi A, Salehi-Abargouei A. Adherence to the dietary approaches to stop hypertension (DASH) diet in relation to all-cause and cause-specific mortality: a systematic review and dose-response meta-analysis of prospective cohort studies *Nutr J* 2020;19(1):37.
30. Tong TYN, Wareham NJ, Khaw K-T, Imamura F, Forouhi NG. Prospective association of the Mediterranean diet with cardiovascular disease incidence and mortality and its population impact in a non-Mediterranean population: the EPIC-Norfolk study. *BMC Med* 2016;14(1):135.